SPY464.72+0.19 0.04%
DIA359.14-2.06 -0.57%
IXIC14,893.75+86.94 0.59%

BRIEF-Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19

reuters.com · 12/29/2021 16:52
BRIEF-Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19

- Revive Therapeutics Ltd RVVTF:

  • REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19

  • REVIVE THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS AND SAFETY CONCERNS REPORTED TO DATE IN PHASE 3 CLINICAL TRIAL

  • REVIVE THERAPEUTICS LTD - EXPECTED TO COMPLETE ENROLLMENT IN Q1-2022

  • REVIVE THERAPEUTICS LTD - TO DATE, STUDY HAS SCREENED APPROXIMATELY 700 SUBJECTS

  • REVIVE THERAPEUTICS LTD - NOT MAKING ANY EXPRESS OR IMPLIED CLAIMS THAT ITS PRODUCT HAS ABILITY TO ELIMINATE OR CURE COVID-19 AT THIS TIME

Source text for Eikon: ID:nGNXc10sNk

Further company coverage: RVVTF


((Reuters.Briefs@thomsonreuters.com;))